US Public Policy and News

 

NASTAD Releases Updated 2017 ADAP Formulary Database

 
 

NASTAD Releases Updated 2017 ADAP Formulary Database
November 29, 2017


Today, NASTAD released an updated 2017 Online AIDS Drug Assistance Program (ADAP) Formulary Database (the Database) which may be accessed via the accompanying User’s Guide. The Database provides an online, searchable, publicly available resource detailing state-by-state ADAP coverage of medications both individually and by drug class including HIV antiretroviral (ARV) treatments, “A1” Opportunistic Infections (A1 OI) medications, treatments for hepatitis B and C, mental health and substance use treatment medications, and various vaccines and laboratory tests.  The Database includes ADAP formulary coverage for all 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands as of August 31, 2017.

 

Key findings from the updated 2017 ADAP Formulary Database include:

  • 12 ADAPs have “open formularies” in which all FDA-approved medications are included, excluding designated exceptions
  • 39 ADAPs cover one or more hepatitis B treatment medication
  • 40 ADAPs cover one or more hepatitis C treatment medication
    • 34 ADAPs cover one or more of the curative direct acting antiviral (DAA) hepatitis C (HCV) treatment medications
      • 25 cover daclatasvir (Daklinza)
      • 30 cover dasabuvir, ombitasvir, paritaprevir, ritonavir (Viekira XR)
      • 28 cover elbasvir and grazoprevir (Zepatier)
      • 11 cover glecaprevir and pibrentasvir (Mavyret)
      • 30 cover ledipasvir and sofosbuvir (Harvoni)
      • 25 cover ombitasvir, paritaprevir and ritonavir (Technivie)
      • 22 cover simeprevir (Olysio)
      • 28 cover sofosbuvir (Sovaldi)
      • 26 cover sofosbuvir, velpatasvir (Epclusa)
      • 11 cover sofosbuvir, velpatasvir, and voxilaprevir (Vosevi)
  • 46 ADAPs cover one or more of the most frequently prescribed mental health treatment medications
  • 27 ADAPs cover one or more substance use treatment medication

ADAPs continue to play a critical role in efforts to end the domestic HIV epidemic by providing and maintaining access to medications for people living with HIV (PLWH). Effective ARV therapy is associated with optimal health outcomes such as viral load suppression, which in turn greatly reduces HIV transmission and rates for new infections. Yet PLWH experience other health concerns beyond HIV, many of which also require access to medications and treatment. As ARVs have greatly extended the life expectancy of PLWH, other conditions that occur because of aging are increasingly important to address and treat. Finally, issues related to hepatitis, substance use, and mental health pose challenges to PLWH in terms of their broader health and well-being and the overall effectiveness of ARV treatment.

 

We applaud ADAPs’ acknowledgment of and commitment to serving the complete health needs of the clients they serve.  Formulary inclusion of curative DAA HCV medications presents an opportunity for people who are co-infected with HIV/HCV to access life-saving treatments for both diseases.

 

Thank you to state AIDS directors and ADAP coordinators who provided NASTAD with the important data that comprises the ADAP Formulary Database. Please contact Amanda Bowes if you have questions.